Comparison of clinical efficacy of remazolam and propofol in patients with acute stroke after endovascular treatment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100045420

Enrollment

Unknown

Registered

2021-04-14

Start date

2021-04-20

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute stroke

Interventions

Experimental group:Remimazolam

Control group:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing endovascular treatment for acute cerebral infarction in our hospital from August 2020 to August 2021; 2. National Institutes of Health Stroke Scale (NIHSS) score <20 points; 3. Irritability, anxiety and other bad moods appear after evaluation All are indicated for sedation treatment; 4. There is no absolute contraindication; 5. The approval of the medical ethics committee and the informed consent of the patients family are obtained.

Exclusion criteria

Exclusion criteria: 1. Stroke onset time> 24 hours; 2. Nervous system recovery or recanalization before endovascular treatment; 3. Modified Rankin scale (mRS) score >= 4; 4. History of drug allergy; 5. Pregnant women; 6. Patients with long-term alcoholism, drug abuse, or use of antidepressants, sedatives, or hypnotics; 7. Patients with dementia; 8. Patients with severe liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
Incidence of sedative hypotension requiring treatment;Incidence of respiratory depression during sedation;	—

Countries

China

Contacts

Public ContactYuan Guangxiong

Xiangtan Central Hospital

Yuanguangxiong74@163.com+86 18973223018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026